Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.262
Index Copernicus (ICV) – 155.19, MNiSW – 15
Rejection rate – 65.13%
License – Creative Commons (CC BY-NC-ND 4.0)
ISSN 1899–5276 (print),   ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2015, vol. 24, nr 5, September-October, p. 899–904

doi: 10.17219/acem/27923

Publication type: review article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

A Comparison of IHC and FISH Cytogenetic Methods in the Evaluation of HER2 Status in Breast Cancer

Marta Wesoła1,A,B,C,D, Michał Jeleń1,E,F

1 Department of Pathomorphology and Oncological Cytology, Wroclaw Medical University, Poland

Abstract

The HER2 gene is responsible for the formation of the HER2 receptor on the surface of epithelial cells. Increased numbers of this receptor are associated with a worse prognosis in cancer. Increased numbers of copies of the HER2 gene occur in about 20–30% of breast cancer patients, so determining HER2 receptor levels is important in the current diagnosis and treatment of breast cancer. One diagnostic technique is the immunohistochemical (IHC) method, which permits indirect measurement of overexpression of HER2 receptors, based on subjective determination of the intensity of the color reaction. Another technique is the use of fluorescent in situ hybridization (FISH), which permits the exact number of copies of the HER2 gene to be specified. Based on the results of FISH tests, patients can be qualified for treatment with antibodies that partially block HER2 receptors. This treatment causes inhibition of tumor growth signals. Determining the HER2 status in breast cancer with the FISH method allows the further progress of the disease to be predicted, the right treatment to be chosen and the response to the treatment to be foreseen. Because of the widespread use of the FISH and IHC methods, comparing the advantages and disadvantages of these two methods seems to be relevant.

Key words

breast cancer, immunohistochemistry, HER-2/neu, fluorescence in situ hybridization

References (40)

  1. Slamon DJ, Godolphin W, Jones LA: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707–712.
  2. Chariyalertsak S, Purisa W, Vinyuvat S: HER-2/neu amplification determined by real-time quantitative PCR and its awith clinical outcome of breast cancer in Thailand. Asian Pacific J Cancer Prev 2011, 12, 1703–1706.
  3. Révillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998, 34, 791–808.
  4. Carr JA, Havstad S, Zarbo RJ: The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg 2000, 135, 1469–1474.
  5. Jana D, Mandal S, Mukhopadhyay M, Mitra D, Mukhopadhyay SK, Sarkar DK: Prognostic significance of HER2/neu and survival of breast cancer patients attending a specialized breast clinic in Kolkata, Eastern India. Asian Pacific J Cancer Prev 2012, 13, 3851–3855.
  6. Ross JS, Fletcher JA, Linette GP: The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003, 8, 307–325.
  7. Hoang MP, Sahin AA, Ordonez NG, Sneige N: HER-2/neu gene amplification compared with HER-2/neu protein cand interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 2000, 113, 852–859.
  8. Hammock L, Lewis M, Phillips C, Cohen C: Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol 2003, 34, 1043–1047.
  9. Singhai R, Patil VW, Patil AV: Immunohistochemical (IHC) HER2/neu and fluorescent in situ hybridization (FISH) gene amplification of breast cancer in Indian women. Asian Pacific J Cancer Prev 2011, 12, 179–183.
  10. Luoh S, Ramsey B, Newell AH, Troxell M, Hu Z, Chin K, Spellman P, Olson S, Keenan E: HER-2 gene amplification in human breast cancer without concurent HER-2 over-expression. Springer Plus 2013, 2, 1–10.
  11. Kao J, Pollack JR: RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Gene Chromosome Canc 2006, 45, 761–769.
  12. Shen TL, Guan JL: Grb7 in intracellular signaling and its role in cel regulation. Front Biosci 2004, 9, 192–200.
  13. Ramsey B, Bai T, Hanlon Newell A: GRB7 protein over-expression and clinical outcome in breast cancer. Breast Cancer Res Treat 2011, 127, 659–669.
  14. Sáez A, Andreu FJ, Seguí MA: HER-2/neu gene amplification by chromogenic in situ hybridization (CISH) compared with fluorescence in situ hybridization (FISH) in breast cancer-A study of two hundred cases. Breast 2006, 15, 519-527.
  15. McManus DT, Patterson AH, Maxwell P: Fluorescence in situ hybridisation detection of erbB2 amplification in breast cancer fine needle aspirates. Mol Pathol 1999, 52, 75–77.
  16. Jeziorski KG: Rak żołądka – leczenie ukierunkowane molekularnie. Onkol Prak Klin 2011, 7, 5, 258–263.
  17. Gould KI, Dayakar S, Vijayalaxmi K, Babu SJ, Vijay ARP: Evaluation of HER2/neu status in breast cancer specimens using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assay. Indian J Med Res 2012, 135, 312–317.
  18. Reed W, Hannisdal E, Boehler PJ: The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14–30 years. Cancer 2000, 88, 804–813.
  19. Melo Rego MJB, Cordeiro MF, Lima Bezerra Cavalcanti C, Carvalho Junior LB, Beltrao EIC: Immunohistochemiluminescence detection: A quantitative tool in breast cancer HER-2 status evaluation. Disease Markers 2013, 34, 373–377.
  20. Beatty BG, Bryant R, Wang W, Ashikaga T, Gibson PC, Leiman G, Weaver DL: HER2/neu detection in fineneedle aspirates of breast cancer: Fluorescence in situ hybridization and immunohistochemical analysis. Am J Clin Pathol 2004, 122, 246–255.
  21. Pauletti G, Dandekar S, Rong H: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000, 18, 3651–3664.
  22. Tubbs RR, Pettay JD, Roche PC: Discrepancies clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false positives do not get the message. J Clin Oncol 2001, 19, 2714–2721.
  23. Dolan M, Snover D: Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2/neu status in routine practice. Am J Clin Pathol 2005, 123, 766–770.
  24. Lan C, Liu JM, Liu TW: erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis. Am J Clin Pathol 2005, 124, 97–102.
  25. Kuo SJ, Wang BB, Chang CS: Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients. Taiwan J Obstet Gynecol, 2007, 46, 146–151.
  26. Kakar S, Puangsuvan N, Stevens JM: HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn 2000, 5, 199–207.
  27. Goud KI, Dayakar S, Vijayalaxmi K, Babu SJ, Vijay ARP: Evaluation of HER2/neu status in breast cancer specimens using imunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assay. Indian J Med Res 2012, 135, 312–317.
  28. Panjwani P, Epari S., Karpate A, Shirsat H, Rajsekharan P, Basak R, Shet T, Chinoy R, Chacko R, Gursale S, Baraskar N, Gupta S, Hawaldar R, Deasi S: Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization and immunohistochemistry: Experience of a tertiary cancer referral centre in India. Indian J Med Res 2010, 132, 287–294.
  29. Prati R, Apple SK, He J, Gornbein JA, Chang HR: Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Breast J 2005, 11, 433–439.
  30. Tsuda H, Akiyama F, Terasaki H, Hasegawa T, Kurosumi M, Shimadzu M: Detection of HER-2/neu (c-erbB-2) DNA amplification in primary breast carcinoma: interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer 2001, 92, 2965–2974.
  31. Steven S: Fluorescence in situ hybridization versus immunohistochemistry: importance of clinical outcome. J Clin Oncol 1999, 17, 3690–3692.
  32. Apple SK, Lowe AC, Rao PN, Shintaku IP, Moatamed NA: Comparison of fluorescent in situ hybridization HER-2/ /neu results on core needel biopsy and excisional biopsy in primary breast cancer. Modern Pathology 2009, 22, 1151–1159.
  33. Rossi V, Sorotto I, Maggiorotto F, Berchialla P, Kubatzki F, Tomasi N, Redana S, Martinello R, Valabrega G, Aglietta M, Ponzone R, Montemurro F: Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer. The Oncologist 2012, 17, 1418–1425.
  34. Lee S, Jung W, Hong S, Koo JS: Evaluation of intratumoral HER-2 heterogeneity by fluorescence in situ hybridization in invasive breast cancer: A single institution study. J Korean Med Sci 2011, 26, 1001–1006.
  35. Dybdal N, Leiberman G, Anderson S: Determination of HER-2/neu gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005, 93, 3–11.
  36. Belengeanu A, Muresan A, Stoicanescu D, Lazar E: Amplification of HER-2 gene in breast cancer: immunohistochemical and FISH assessment. Rom J Morphol Embriol 2010, 51, 321–326.
  37. Slamon DJ, Leyland-Jones B, Shak S: Use of chemotherapy plus a monoclonal antibody against for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344, 783–792.
  38. Chariyalertsak S, Purisa W, Vinyuvat S: HER-2/neu amplification determined by real-time quantitative PCR and its awith clinical outcome of breast cancer in Thailand. Asian Pacific J Cancer Prev 2011, 12, 1703–1706.
  39. Cao FA, Li Z, Kai H, Lu J: Chemiluminescence platforms in immunoassay and DNA analyses. Analytical Sciences 2009, 25, 587–597.
  40. Melo Rego MJB, Cordeiro MF, Lima Bezerra Cavalcanti C, Carvalho Junior LB, Beltrao EIC: Immunohistochemiluminescence detection: A quantitative tool in breast cancer HER-2 status evaluation. Dis Markers 2013, 34, 373–377.